Literature DB >> 15565430

Quantitative analysis of the effects of some "atypical" and "conventional" antipsychotics on progressive ratio schedule performance.

Z Zhang1, J F Rickard, K Asgari, S Body, C M Bradshaw, E Szabadi.   

Abstract

RATIONALE: Performance on progressive ratio schedules has been proposed as a means of assessing the effects of drugs on the value or "efficacy" of reinforcers. A mathematical model affords a basis for quantifying the effects of drugs on progressive ratio schedule performance. According to this model, the relation between response rate and ratio size is described by a bitonic (inverted-U) function. One parameter of the function, alpha, expresses the motivational or "activating" effect of the reinforcer (duration of activation of responding produced by the reinforcer), whereas another parameter, delta, expresses the minimum time needed to execute a response, and is regarded as an index of "motor capacity". In a previous experiment we found that the "atypical" antipsychotic clozapine increased alpha, indicating an increase in the efficacy of a food reinforcer.
OBJECTIVE: We examined the effects of four "atypical" and four "conventional" antipsychotics on progressive ratio schedule performance.
METHODS: Rats responded for a sucrose reinforcer (0.6 M, 50 microl) on a time-constrained progressive ratio schedule (50-min sessions). After 90 preliminary training sessions, they received acute doses of antipsychotics (doses in mg kg(-1)): atypical: clozapine (2, 4, 8, IP; n=15), quetiapine (1.25, 2.5, 5, 10, SC; n=23), olanzapine (0.25, 0.5, 1, IP; n=15), ziprasidone (0.625, 1.25, 2.5, IP, n=15); conventional: haloperidol (0.025, 0.05, 0.1, IP, n=15), pimozide (0.125, 0.25, 0.5, IP; n=15), raclopride (0.25, 0.5, 1, SC; n=12), cis-flupenthixol (0.2, 0.4, 0.8, SC; n=15). Values of a and delta were estimated from the response rate functions obtained under each treatment condition, and were compared between drug and vehicle-alone treatments.
RESULTS: The atypical antipsychotics significantly increased alpha (indicating enhancement of reinforcer efficacy), and also increased delta (indicating reduction of motor capacity). Haloperidol, pimozide and raclopride significantly increased delta; none of the conventional antipsychotics significantly altered alpha.
CONCLUSIONS: The results extend previous findings with clozapine to other atypical antipsychotics and suggest that enhancement of the efficacy of reinforcers may be a common feature of atypical antipsychotics not shared by conventional antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15565430     DOI: 10.1007/s00213-004-2049-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

1.  Effects of reinforcer sweetness and the D2/D3 antagonist raclopride on progressive ratio operant performance.

Authors:  S. Cheeta; S. Brooks; P. Willner
Journal:  Behav Pharmacol       Date:  1995-03       Impact factor: 2.293

Review 2.  The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

Authors:  R A Bantick; J F Deakin; P M Grasby
Journal:  J Psychopharmacol       Date:  2001-03       Impact factor: 4.153

3.  Limbic selectivity of clozapine.

Authors:  L S Pilowsky; R S Mulligan; P D Acton; P J Ell; D C Costa; R W Kerwin
Journal:  Lancet       Date:  1997-08-16       Impact factor: 79.321

4.  Nucleus accumbens dopamine depletions and time-constrained progressive ratio performance: effects of different ratio requirements.

Authors:  S Hamill; J T Trevitt; K L Nowend; B B Carlson; J D Salamone
Journal:  Pharmacol Biochem Behav       Date:  1999-09       Impact factor: 3.533

5.  Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.

Authors:  A Dekeyne; J M Rivet; A Gobert; M J Millan
Journal:  Neuropharmacology       Date:  2001-06       Impact factor: 5.250

6.  Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

Authors:  A W Schmidt; L A Lebel; H R Howard; S H Zorn
Journal:  Eur J Pharmacol       Date:  2001-08-17       Impact factor: 4.432

Review 7.  Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Nishan S Gunasekara; Caroline M Spencer; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  The effects of atypical antipsychotic medications on psychosocial outcomes.

Authors:  Patrick W Corrigan; Rebecca R Reinke; Sarah A Landsberger; Ajeet Charate; Gregory A Toombs
Journal:  Schizophr Res       Date:  2003-09-01       Impact factor: 4.939

Review 9.  Brain dopamine and reward.

Authors:  R A Wise; P P Rompre
Journal:  Annu Rev Psychol       Date:  1989       Impact factor: 24.137

10.  Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food.

Authors:  R A Wise; J Spindler; H deWit; G J Gerberg
Journal:  Science       Date:  1978-07-21       Impact factor: 47.728

View more
  17 in total

Review 1.  A theory of behaviour on progressive ratio schedules, with applications in behavioural pharmacology.

Authors:  C M Bradshaw; P R Killeen
Journal:  Psychopharmacology (Berl)       Date:  2012-07-03       Impact factor: 4.530

2.  Effect of reinforcer magnitude on performance maintained by progressive-ratio schedules.

Authors:  J F Rickard; S Body; Z Zhang; C M Bradshaw; E Szabadi
Journal:  J Exp Anal Behav       Date:  2009-01       Impact factor: 2.468

Review 3.  Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.

Authors:  P De Deurwaerdère; M Lagière; M Bosc; S Navailles
Journal:  Exp Brain Res       Date:  2013-04-25       Impact factor: 1.972

4.  Comparison of the effects of clozapine and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on progressive ratio schedule performance: evidence against the involvement of 5-HT1A receptors in the behavioural effects of clozapine.

Authors:  Z Zhang; J F Rickard; S Body; K Asgari; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

5.  Clozapine increases reward evaluation but not overall ingestive behaviour in rats licking for sucrose.

Authors:  Adriana Galistu; Cristina Modde; Maria Cristina Pireddu; Flavia Franconi; Gino Serra; Paolo S D'Aquila
Journal:  Psychopharmacology (Berl)       Date:  2011-03-01       Impact factor: 4.530

6.  Effects of SKF-83566 and haloperidol on performance on progressive ratio schedules maintained by sucrose and corn oil reinforcement: quantitative analysis using a new model derived from the Mathematical Principles of Reinforcement (MPR).

Authors:  C M Olarte-Sánchez; L Valencia-Torres; H J Cassaday; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2013-07-05       Impact factor: 4.530

7.  Modeling operant behavior in the Parkinsonian rat.

Authors:  Irene Avila; Mark P Reilly; Federico Sanabria; Diana Posadas-Sánchez; Claudia L Chavez; Nikhil Banerjee; Peter Killeen; Eddie Castañeda
Journal:  Behav Brain Res       Date:  2008-11-27       Impact factor: 3.332

8.  Effect of quinolinic acid-induced lesions of the nucleus accumbens core on performance on a progressive ratio schedule of reinforcement: implications for inter-temporal choice.

Authors:  G Bezzina; S Body; T H C Cheung; C L Hampson; J F W Deakin; I M Anderson; E Szabadi; C M Bradshaw
Journal:  Psychopharmacology (Berl)       Date:  2008-01-03       Impact factor: 4.530

9.  A quantitative analysis of the effects of qualitatively different reinforcers on fixed ratio responding in inbred strains of mice.

Authors:  Blake A Hutsell; M Christopher Newland
Journal:  Neurobiol Learn Mem       Date:  2013-01-26       Impact factor: 2.877

10.  Antidepressant Drugs Correct the Imbalance Between proBDNF/p75NTR/Sortilin and Mature BDNF/TrkB in the Brain of Mice with Chronic Stress.

Authors:  C R Yang; X Y Zhang; Y Liu; J Y Du; R Liang; M Yu; F Q Zhang; X F Mu; F Li; L Zhou; F H Zhou; F J Meng; S Wang; D Ming; X F Zhou
Journal:  Neurotox Res       Date:  2019-09-06       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.